X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Dichlorphenamide is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Lead Product(s): Dichlorphenamide
Therapeutic Area: Neurology Product Name: Keveyis-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
The acquisition diversifies revenue base with two rapidly growing brands in Xeris’ Gvoke® and Strongbridge’s KEVEYIS®.
Lead Product(s): Dichlorphenamide
Therapeutic Area: Rare Diseases and Disorders Product Name: Keveyis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xeris Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
